Archimedes Vascular Secures $2.2 Million in Series A Funding Led by Sherpa Healthcare Partners

Archimedes Vascular's Successful Series A Financing

Archimedes Vascular, Inc., an innovative medical device company dedicated to tackling severe hypertension, has recently announced the completion of its Series A financing round, raising $2.2 million. This funding, which was spearheaded by Sherpa Healthcare Partners, is pivotal for the company's ongoing development of its groundbreaking implant designed to aid individuals suffering from uncontrolled hypertension.

Dr. Farrell O. Mendelsohn, the founder of Archimedes Vascular, expressed immense gratitude towards Sherpa Healthcare Partners and the newly appointed chairman of the board, Raymond W. Cohen. He noted the significance of this financial support in facilitating the continuation of pre-clinical studies and ultimately securing FDA clearance for upcoming human clinical trials. "This investment acknowledges the promise of our project and supports our goal of innovating solutions for patients with severe hypertension," stated Mendelsohn.

Cohen’s extensive background in the medical technology sector positions him as a strategic leader for Archimedes Vascular. He previously co-founded Axonics, Inc., which became publicly listed and recognized as one of the fastest-growing companies in the Americas during his tenure. Following the successful acquisition of Axonics by Boston Scientific, Cohen took on the role of Chairman at SoniVie, Ltd., a company focused on developing treatments for hypertension similar to Archimedes.

In his new capacity at Archimedes, Cohen emphasized the importance of addressing the needs of patients who are unable to manage their blood pressure through traditional pharmaceutical means or renal denervation. He is keen on collaborating with Dr. Mendelsohn to establish and validate the effectiveness of Archimedes' innovative approach to managing hypertension.

As a company based in Birmingham, Alabama, Archimedes Vascular is committed to developing an implantable device that leverages advanced technology to induce baroreflex in the aortic arch, thereby providing an alternative for patients suffering from chronic hypertension. Their flagship product, the Barostent™, is designed to address a significant gap in treatment options available for those for whom conventional therapies have failed.

The partnership with Sherpa Healthcare Partners is a testament to Archimedes Vascular’s potential, resonating with investors looking to back pioneering companies in the healthcare sector. Sherpa’s investment strategy involves funding innovative organizations with a robust growth trajectory across various regions, including China, Europe, and North America.

Archimedes Vascular is now focused on leveraging this investment to advance its product through rigorous testing and regulatory pathways. By combining Cohen’s leadership and industry connections with the substantial financial backing, Archimedes is poised to make a lasting impact on the hypertension treatment landscape. As the company enters this critical phase of development, all eyes will be on their progress as they aim for successful FDA approval and the launch of their clinical trials.

This advancement offers hope for patients struggling with severe hypertension, promising new solutions tailored for those who have yet to find relief through available medical interventions. In a world where almost 1 in 3 adults globally suffer from hypertension, the potential success of Archimedes Vascular’s technology could be revolutionary, positioning the company not only as a leader in the medical devices space but also as a beacon of hope for patients worldwide.